Bioscope AI
Bioscope AI is a private US health-tech company that sells a HIPAA-compliant cloud platform combining whole-genome sequencing, microbiome analysis, and EMR data with AI-powered clinical decision support, targeted at concierge physicians and medical practices seeking to deliver precision medicine during patient visits.
- Company typePrivate
- Founded2025
- HeadquartersCarmel, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Bioscope AI does
Bioscope AI is a privately held US company (incorporated in Indiana, headquartered in Carmel) that sells a cloud-based clinical decision-support platform for licensed physicians and medical practices. The platform synthesizes whole-genome sequencing (30x coverage, ~3.2 billion base pairs, 20,000-25,000 genes), microbiome analysis, electronic medical record data, and laboratory results into a single per-patient longitudinal view, then surfaces AI-generated clinical insights, polygenic risk scores, pharmacogenomic flags (22 PGx variants), and dimension-by-dimension findings (renal, cardiovascular, metabolic, neurocognitive, longevity, cancer, immune, gut, hepatic, blood) through an AI chat interface. The company's core technological differentiator is an evidence-grounded reasoning layer with controlled chains designed to prevent hallucination, delivered on HIPAA-compliant infrastructure with AES-256 encryption, TLS 1.3, MFA, and BAA-ready contracting.
The company operates a hybrid go-to-market: an enterprise field-sales motion offering 30-minute demos covering EMR integration, patient enrollment, and a sample case, paired with a self-service 'Try It On Yourself' product-led growth funnel for individual physicians. Revenue is generated through SaaS subscriptions to the cloud platform (annual, auto-renewing) and laboratory testing services for whole-genome sequencing and microbiome analysis performed by contracted testing labs. The primary customer segment is horizontal: concierge physicians, primary care doctors, and medical practices seeking to deliver precision medicine with limited time per visit. The only publicly named customer is Austin Concierge Medicine; the operating footprint is US-only. The leadership team is in buildout mode, with a CTO (Felix Wyss) appointed March 2026 and a CMO (Dr. Helen Messier) appointed February 2026, and a 'Try It On Yourself' program launched in October 2025. No funding rounds, revenue figures, or customer counts are disclosed.
Bioscope AI firmographics
Firmographics- Name
- Bioscope AI
- Legal name
- Bioscope.ai, Inc.
- Website
- https://bioscope.ai
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bioscope AI is a private US health-tech company that sells a HIPAA-compliant cloud platform combining whole-genome sequencing, microbiome analysis, and EMR data with AI-powered clinical decision support, targeted at concierge physicians and medical practices seeking to deliver precision medicine during patient visits.
- Ownership category
- akta.pro rank
Bioscope AI industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Bioscope AI is headquartered
LocationHeadquarters
- HQ city
- Carmel
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bioscope AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- SaaS Subscription for Healthcare Practices: Subscription-based access to the Bioscope.ai cloud-based software platform for medical groups and practices. Physicians pay subscription fees to access AI-powered genomic analysis and clinical decision support tools integrated with their patient workflow.
- Laboratory Testing Services: Whole genome sequencing and microbiome analysis services ordered by healthcare providers on behalf of patients. The testing includes sample collection kits and processing through contracted testing laboratories.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription-based SaaS platform access for medical practices |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Bioscope AI product offering
Product offeringCore offering
Bioscope AI sells a cloud-based, HIPAA-compliant clinical decision support SaaS platform that synthesizes whole-genome sequencing (~30x coverage), microbiome analysis, electronic medical records, and lab results into physician-ready clinical insights. Licensed clinicians access an AI chat interface with controlled reasoning chains that flags 22 pharmacogenomic variants and surfaces findings across 15 health dimensions (Metabolic, Cardiovascular, Neurocognitive, Longevity, Immune, Gut, Renal, Hepatic, Cancer, etc.). The company also offers laboratory testing services (whole-genome sequencing and microbiome analysis) and a "Try It On Yourself" self-signup program for individual physician self-analysis.
Product overview
Bioscope.ai is a clinical AI platform built as a unified SaaS offering combining genetic analysis with AI-powered clinical decision support. The core Bioscope.ai Platform serves as the central hub, supported by whole-genome sequencing and microbiome analysis laboratory services. Key modules include an AI Chat Interface for natural language queries, pharmacogenomics (PGx) analysis, and EHR Integration Services. The Try It On Yourself Program enables physicians to personally experience the platform by analyzing their own health data. The platform is accessed via the HIPAA-compliant app.us.bioscope.ai web application.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioscope.ai Platform HIPAA-compliant, cloud-based clinical decision support platform for physicians and medical practices that reads whole-genome sequencing, microbiome, lab, and full patient history data and synthesizes them into clinical insights before patient visits. Includes the AI Chat Interface, pharmacogenomic analysis, and EMR integration.
- Whole-Genome Sequencing Laboratory testing service that sequences patient samples at ~30x average coverage, reading approximately 3.2 billion base pairs across 20,000–25,000 genes with all variants reviewed against the latest clinical databases. Ordered by healthcare providers on behalf of patients, with at-home or in-office collection kits.
- Microbiome Analysis Laboratory testing service that analyzes DNA of microorganisms from stool samples to provide clinical insights into microbial composition and function, ordered by healthcare providers for patients as an optional add-on to whole-genome sequencing.
- Try It On Yourself Program Self-service offering for individual physicians to use Bioscope AI's clinical AI and genomics capabilities on themselves, including self-enrollment, personal medical data upload, and ordering of whole-genome and microbiome testing kits, intended as a validation path before practice-wide recommendation.
Quantifiable outcome
- Most physicians are operational within a week of EMR integration
- +1 more outcomes
Companies that use Bioscope AI
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Bioscope AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature5 records
Bioscope AI partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Contracted Testing LaboratoriescoreBioscope AI contracts with qualified laboratories to perform whole genome sequencing and microbiome analysis on patient samples. A current list of Testing Laboratories is maintained on the Subprocessors page. These laboratories hold appropriate certifications and accreditations for genetic testing services.
- Auth0coreAuth0 provides secure authentication and session management for the HIPAA-compliant healthcare platform (app.us.bioscope.ai). Uses encrypted session identifiers with HttpOnly and Secure flags, device identifiers for security monitoring, and automatic session termination after 15 minutes of inactivity.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Bioscope AI competitors and assessment
Company assessmentBroad incumbents
- Foundation Medicine (Roche): Foundation Medicine provides molecular profiling and genomic analysis to oncologists at scale within the Roche ecosystem; a broad incumbent in clinical genomics whose CDSS-adjacent services compete for the same physician mindshare bioscope.ai targets.
- GeneDx (formerly Sema4): GeneDx delivers clinical genomic sequencing and interpretation (rare disease, hereditary cancer, PGx) at scale — a broader incumbent whose CDSS-adjacent workflow overlaps with bioscope.ai's clinical genomics offering.
- Caris Life Sciences: Caris provides molecular profiling (WGS, WTS, proteomics) and AI-driven insights for oncologists, comparable to bioscope.ai's whole-genome + AI clinical decision support model within oncology-focused precision medicine.
- Verily Life Sciences (Alphabet): Verily is a health-data and precision-medicine platform within Alphabet pursuing AI-driven clinical research and care delivery; broadly comparable to bioscope.ai's data-aggregation approach to clinical AI.
Direct peers
- SOPHiA Genetics: SOPHiA Genetics operates an AI-driven genomics interpretation platform used by hospitals and clinicians worldwide for clinical decision support, closely paralleling bioscope.ai's evidence-grounded AI for genomic/multi-omic clinical insights.
- Tempus Labs: Tempus AI combines multi-modal data (genomics, transcriptomics, imaging, clinical records) with AI to deliver clinical decision support and precision medicine insights to physicians — directly comparable to bioscope.ai's WGS + EMR + AI CDSS model across target customer profile.
- Helix: Helix operates a whole-exome / whole-genome sequencing platform powering clinical and population genomics applications — closely aligned with bioscope.ai's 30x WGS foundation and clinical decision support build.
- Color Health: Color combines clinical-grade genetic testing with a clinician-facing platform spanning hereditary cancer, pharmacogenomics, and population health — directly comparable to bioscope.ai's WGS + PGx + clinical workflow offering.
Emerging players
- Owkin: Owkin applies AI to multi-modal clinical and omics data for treatment decision support and drug discovery, overlapping with bioscope.ai's clinician-facing AI analytics on genomic and clinical data.
- Genomind: Genomind provides PGx and mental-health genetic testing for clinicians — a smaller, niche player in genetic clinical decision support that overlaps with bioscope.ai's PGx module and physician-facing workflow.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Bioscope AI social profiles
Digital presenceBioscope AI compliance and trust
Trust signalCompliance6 records
Bioscope AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioscope AI leadership team
Management profileNumber of profiles
Profiles3 records
Bioscope AI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioscope AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioscope AI
What does Bioscope AI do?
Bioscope AI sells a cloud-based, HIPAA-compliant clinical decision support SaaS platform that synthesizes whole-genome sequencing (~30x coverage), microbiome analysis, electronic medical records, and lab results into physician-ready clinical insights. Licensed clinicians access an AI chat interface with controlled reasoning chains that flags 22 pharmacogenomic variants and surfaces findings across 15 health dimensions (Metabolic, Cardiovascular, Neurocognitive, Longevity, Immune, Gut, Renal, Hepatic, Cancer, etc.). The company also offers laboratory testing services (whole-genome sequencing and microbiome analysis) and a "Try It On Yourself" self-signup program for individual physician self-analysis.
Is Bioscope AI a public or private company?
Bioscope AI is a private company. It is classified as unknown and is currently operating.
When was Bioscope AI founded?
Bioscope AI was founded in 2025. It employs 11 to 50 people.
Where is Bioscope AI based?
Bioscope AI is headquartered in Carmel, United States, in the North America region.
How does Bioscope AI make money?
Two revenue lines are on record. SaaS Subscription for Healthcare Practices are the primary driver. The others are laboratory Testing Services.
Who are Bioscope AI's main competitors?
Broad incumbents on record are Foundation Medicine (Roche), GeneDx (formerly Sema4), Caris Life Sciences and Verily Life Sciences (Alphabet). Direct peers are SOPHiA Genetics, Tempus Labs, Helix and Color Health. Emerging players are Owkin and Genomind.
Does Bioscope AI have an API?
No public API is recorded for Bioscope AI.
What industry is Bioscope AI in?
Bioscope AI's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 6215 and its SIC code is 2835.